

A new prognostic index (MIPI) for patients with advanced

Blood

111, 558-565

DOI: [10.1182/blood-2007-06-095331](https://doi.org/10.1182/blood-2007-06-095331)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Mantle cell lymphoma: Evolving novel options. <i>Current Oncology Reports</i> , 2007, 9, 391-398.	1.8	14
2	Mantle cell lymphoma: Frontline and salvage therapy. <i>Current Hematologic Malignancy Reports</i> , 2008, 3, 204-209.	1.2	2
4	Advances in the understanding of mantle cell lymphoma. <i>British Journal of Haematology</i> , 2008, 142, 149-165.	1.2	154
5	Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. <i>Leukemia and Lymphoma</i> , 2008, 49, 2081-2090.	0.6	102
6	Mantle cell lymphoma: an overview of diagnostic and therapeutic advances. <i>Community Oncology</i> , 2008, 5, 465-472.	0.2	1
7	Prognostic Systems for Lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 839-861.	0.9	12
8	Therapy of Mantle Cell Lymphoma: Current Standards and Future Strategies. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 953-963.	0.9	27
9	Prognosis of mantle cell lymphoma: is it all about proliferation?. <i>Leukemia and Lymphoma</i> , 2008, 49, 2029-2030.	0.6	2
10	Bortezomib in mantle cell lymphoma. <i>Future Oncology</i> , 2008, 4, 149-168.	1.1	31
11	Current treatment standards and future strategies in mantle cell lymphoma. <i>Annals of Oncology</i> , 2008, 19, iv41-iv44.	0.6	21
12	CD23+ Mantle Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2008, 130, 166-177.	0.4	54
14	Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. <i>Blood</i> , 2008, 111, 2385-2387.	0.6	220
15	Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. <i>Blood</i> , 2008, 112, 2583-2583.	0.6	27
16	Mantle cell lymphoma: advances in biology and therapy. <i>Current Opinion in Hematology</i> , 2008, 15, 415-421.	1.2	40
17	Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?. <i>Current Opinion in Oncology</i> , 2008, 20, 487-494.	1.1	13
18	Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909. <i>Journal of Clinical Oncology</i> , 2009, 27, 6101-6108.	0.8	182
19	The simplified mantle cell lymphoma international prognostic index predicts overall survival but not progression-free survival in patients with mantle cell lymphoma treated with fludarabine and cyclophosphamide±rituximab: results of a randomized phase II trial. <i>Leukemia and Lymphoma</i> , 2009, 50, 1709-1711.	0.6	10
20	Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. <i>Annals of Oncology</i> , 2009, 20, 520-525.	0.6	302

#	ARTICLE	IF	CITATIONS
21	Molecular outcome prediction in mantle cell lymphoma. <i>Future Oncology</i> , 2009, 5, 63-73.	1.1	11
22	Mantle cell lymphoma: state-of-the-art management and future perspective. <i>Leukemia and Lymphoma</i> , 2009, 50, 1937-1970.	0.6	19
23	Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient. <i>Expert Review of Hematology</i> , 2009, 2, 173-182.	1.0	5
24	Mantle cell lymphoma in the orbital and adnexal region. <i>British Journal of Ophthalmology</i> , 2009, 93, 1047-1051.	2.1	58
25	Phase II Study of Yttrium-90- ⁹⁰ Y-ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5213-5218.	0.8	87
26	Mantle cell lymphoma. <i>Haematologica</i> , 2009, 94, 1488-1492.	1.7	77
27	Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. <i>Cancer</i> , 2009, 115, 1041-1048.	2.0	27
28	Frontline therapy in mantle cell lymphoma: The role of high-dose therapy and integration of new agents. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 213-217.	1.2	5
29	Mantle cell lymphoma: Are current therapies changing the course of disease?. <i>Current Oncology Reports</i> , 2009, 11, 371-377.	1.8	2
30	Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network. <i>Journal of Hematopathology</i> , 2009, 2, 103-111.	0.2	149
32	High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. <i>British Journal of Haematology</i> , 2009, 144, 524-530.	1.2	61
33	Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value. <i>British Journal of Haematology</i> , 2009, 146, 607-618.	1.2	27
34	Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. <i>British Journal of Haematology</i> , 2009, 147, 83-88.	1.2	50
35	The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). <i>Leukemia</i> , 2009, 23, 153-161.	3.3	151
36	High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. <i>Bone Marrow Transplantation</i> , 2009, 43, 509-511.	1.3	25
37	Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1209-1213.	0.8	322
38	Current treatment standards and emerging strategies in mantle cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 542-551.	0.9	88
39	The Role of Biomarkers in the Management of Patients with Lymphoma: Promise Versus Reality. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 121-123.	1.4	1

#	ARTICLE	IF	CITATIONS
41	Mantle Cell Lymphoma: Biological Insights and Treatment Advances. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 267-277.	1.4	22
42	Temsirolimus for the treatment of mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2009, 2, 631-640.	1.0	18
43	Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1239-1248.	0.6	12
44	Mantle cell lymphoma “does primary intensive immunochemotherapy improve overall survival for younger patients?”. <i>Leukemia and Lymphoma</i> , 2009, 50, 1249-1256.	0.6	4
45	FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome. <i>Nuclear Medicine Communications</i> , 2009, 30, 770-778.	0.5	44
46	Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. <i>Blood</i> , 2009, 113, 4604-4613.	0.6	172
47	Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. <i>Blood</i> , 2009, 113, 4144-4152.	0.6	196
48	How I treat mantle cell lymphoma. <i>Blood</i> , 2009, 114, 1469-1476.	0.6	170
49	NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, S-1-S-34.	2.3	11
50	Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma. <i>International Journal of Oncology</i> , 2010, 36, 699-706.	1.4	22
51	Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting. <i>Haematologica</i> , 2010, 95, 1503-1509.	1.7	27
52	The Mantle Cell Lymphoma International Prognostic Index: Does it work in routine practice?. <i>Oncology Letters</i> , 2010, 1, 187-188.	0.8	8
53	Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. <i>Blood</i> , 2010, 115, 3215-3223.	0.6	243
54	The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). <i>Blood</i> , 2010, 115, 1530-1533.	0.6	167
55	microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. <i>Blood</i> , 2010, 115, 2630-2639.	0.6	332
56	Endoscopic Follow-up of 3 Cases with Gastrointestinal Tract Involvement of Mantle Cell Lymphoma. <i>Internal Medicine</i> , 2010, 49, 231-235.	0.3	7
57	Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. <i>Haematologica</i> , 2010, 95, 1350-1357.	1.7	36
58	Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1633-1642.	3.3	76

#	ARTICLE	IF	CITATIONS
59	A novel quantitative PCR of proliferation markers (Ki-67, topoisomerase II β , and TPX2): an immunohistochemical correlation, testing, and optimizing for mantle cell lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 456, 671-679.	1.4	31
60	Therapeutic concepts in mantle cell lymphoma. <i>European Journal of Haematology</i> , 2010, 85, 371-386.	1.1	3
61	High incidence of false-positive <i>Aspergillus</i> galactomannan test in multiple myeloma. <i>American Journal of Hematology</i> , 2010, 85, 449-451.	2.0	25
62	Mixed phenotype acute leukemia with t(11;19)(q23;p13.3)/ MLL \rightarrow MLLT1(ENL), B/T lymphoid type: A first case report. <i>American Journal of Hematology</i> , 2010, 85, 451-454.	2.0	14
63	Validation of the mantle cell lymphoma international prognostic index: A single-center retrospective analysis. <i>American Journal of Hematology</i> , 2010, 85, 454-456.	2.0	5
64	Primary mantle cell lymphoma of the thyroid. <i>Leukemia Research</i> , 2010, 34, 548-550.	0.4	9
65	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). <i>Leukemia Research</i> , 2010, 34, 1340-1343.	0.4	56
66	Role of chemotherapy in gastric MALT lymphoma, diffuse large B-cell lymphoma and other lymphomas. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 19-26.	1.0	15
67	Diagnosis and staging in gastrointestinal lymphoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 3-12.	1.0	30
68	Ten-year follow-up after intense chemoimmunotherapy with Rituximab \rightarrow HyperCVAD alternating with Rituximab \rightarrow high dose methotrexate/cytarabine (R \rightarrow EMA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010, 150, 200-208.	1.2	213
69	Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R \rightarrow CHOP \rightarrow 21. <i>British Journal of Haematology</i> , 2010, 151, 221-231.	1.2	47
70	Mantle cell lymphoma: transcriptional regulation by microRNAs. <i>Leukemia</i> , 2010, 24, 1335-1342.	3.3	72
71	Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation. <i>Stem Cells and Cloning: Advances and Applications</i> , 2010, 3, 93.	2.3	2
72	Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma. <i>OncoTargets and Therapy</i> , 2010, 3, 167.	1.0	6
73	O transplante de c�lulas-tronco hematopo�ticas no tratamento dos linfomas n�o Hodgkin. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 0, 32, 106-114.	0.7	0
74	Biologie et traitements cib�s des lymphomes �cellules du manteau. <i>Hematologie</i> , 2010, 16, 363-371.	0.0	0
75	High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 406-414.	0.6	16
76	InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. <i>Blood</i> , 2010, 116, e90-e98.	0.6	200

#	ARTICLE	IF	CITATIONS
77	Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. <i>Annals of Oncology</i> , 2010, 21, 133-139.	0.6	65
78	Flavopiridol, Fludarabine, and Rituximab in Mantle Cell Lymphoma and Indolent B-Cell Lymphoproliferative Disorders. <i>Journal of Clinical Oncology</i> , 2010, 28, 418-423.	0.8	84
79	Relapsed Mantle Cell Lymphoma Presenting as "Sister Mary Joseph Nodule": Case Reports in <i>Medicine</i> , 2010, 2010, 1-3.	0.3	6
80	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4191-4198.	0.8	184
81	Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?. <i>Leukemia and Lymphoma</i> , 2010, 51, 357-359.	0.6	2
82	Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?. <i>Bone Marrow Transplantation</i> , 2010, 45, 1379-1387.	1.3	3
83	Front-line treatment of mantle cell lymphoma. <i>Haematologica</i> , 2010, 95, 1241-1243.	1.7	13
84	Management of Mantle Cell Lymphoma: Key Challenges and Next Steps. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 336-346.	0.2	11
85	A Decade of Progress in Lymphoma: Advances and Continuing Challenges. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 414-423.	0.2	43
86	13 Diffuse large B-cell lymphoma. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 8-9.	2.2	0
87	14 Recent progress in the treatment for T-cell malignancies. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 9.	2.2	0
88	15 Mantle cell lymphoma: Current standards and new approaches. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 9-10.	2.2	0
89	Handbook of Evidence-Based Radiation Oncology. , 2010, , .		45
90	Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. <i>Leukemia and Lymphoma</i> , 2010, 51, 1269-1277.	0.6	31
91	Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1419-1427.	2.0	93
92	Lymphoma " Emerging realities in sub-Saharan Africa. <i>Transfusion and Apheresis Science</i> , 2010, 42, 141-150.	0.5	14
93	Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2010, 109, 98-104.	1.6	31
95	Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference. <i>Leukemia and Lymphoma</i> , 2010, 51, 1612-1622.	0.6	21

#	ARTICLE	IF	CITATIONS
96	Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. <i>Cancer Research</i> , 2010, 70, 1408-1418.	0.4	429
97	Mantle cell lymphoma with uveal metastasis. <i>Leukemia and Lymphoma</i> , 2010, 51, 1354-1355.	0.6	14
98	Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1488-1494.	0.6	39
99	Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms. <i>Leukemia and Lymphoma</i> , 2011, 52, 142-144.	0.6	2
100	Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. <i>Leukemia and Lymphoma</i> , 2011, 52, 387-393.	0.6	35
101	Suppression of tumorigenicity of rhabdoid tumor derived G401 cells by the multivalent HB-19 pseudopeptide that targets surface nucleolin. <i>Biochimie</i> , 2011, 93, 426-433.	1.3	31
102	Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. <i>Blood</i> , 2011, 118, 2530-2540.	0.6	226
103	Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 245-255.	1.0	35
104	Histopathology of Mantle Cell Lymphoma. <i>Seminars in Hematology</i> , 2011, 48, 148-154.	1.8	30
105	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: Where Are We Now and Which Way Should We Go?. <i>Seminars in Hematology</i> , 2011, 48, 227-239.	1.8	13
106	Is There a Role for "Watch and Wait" in Patients With Mantle Cell Lymphoma?. <i>Seminars in Hematology</i> , 2011, 48, 189-193.	1.8	24
107	Prognostic Relevance of Clinical Risk Factors in Mantle Cell Lymphoma. <i>Seminars in Hematology</i> , 2011, 48, 185-188.	1.8	10
108	Treatment of Younger Patients With Mantle Cell Lymphoma. <i>Seminars in Hematology</i> , 2011, 48, 194-207.	1.8	10
109	Therapy of Mantle Cell Lymphoma: New Treatment Options in an Old Disease or Vice Versa?. <i>Seminars in Hematology</i> , 2011, 48, 145-147.	1.8	5
112	Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. <i>Blood</i> , 2011, 117, 542-552.	0.6	97
113	Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. <i>Blood</i> , 2011, 117, 4530-4541.	0.6	75
114	Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. <i>Blood</i> , 2011, 118, 4808-4816.	0.6	81
115	Indolent mantle cell lymphoma. <i>Haematologica</i> , 2011, 96, 1086-1088.	1.7	27

#	ARTICLE	IF	CITATIONS
116	Mantle cell lymphoma. <i>Hematologie</i> , 2011, 17, 322-330.	0.0	0
117	Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. <i>Haematologica</i> , 2011, 96, 1121-1127.	1.7	171
118	Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. <i>Haematologica</i> , 2011, 96, 1008-1014.	1.7	76
119	VcRâ€CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. <i>British Journal of Haematology</i> , 2011, 155, 190-197.	1.2	48
120	The complex landscape of genetic alterations in mantle cell lymphoma. <i>Seminars in Cancer Biology</i> , 2011, 21, 322-334.	4.3	100
121	Personalized Treatment of Lymphoma: Promise and Reality. <i>Seminars in Oncology</i> , 2011, 38, 225-235.	0.8	10
122	Mantle cell lymphoma: The promise of new treatment options. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 69-86.	2.0	48
123	Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkinâ€™s lymphoma: a consortium for improving survival of lymphoma (CISL) trial. <i>Investigational New Drugs</i> , 2011, 29, 154-160.	1.2	11
124	Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan. <i>International Journal of Hematology</i> , 2011, 93, 684-686.	0.7	5
125	Utility of positron emission tomography scans in mantle cell lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 841-845.	2.0	55
126	Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. <i>Cancer</i> , 2011, 117, 1901-1910.	2.0	40
127	Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. <i>Cancer</i> , 2011, 117, 2442-2451.	2.0	52
128	Should there be a standard therapy for mantle cell lymphoma?. <i>Future Oncology</i> , 2011, 7, 227-237.	1.1	9
129	Initial therapy of mantle cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 381-392.	1.1	6
130	Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. <i>Leukemia and Lymphoma</i> , 2011, 52, 1675-1680.	0.6	38
131	Are we improving the survival of patients with mantle cell lymphoma: if so, what is the explanation?. <i>Leukemia and Lymphoma</i> , 2011, 52, 1828-1830.	0.6	0
132	A Pilot Study to Evaluate ¹⁸ F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1898-1902.	2.8	29
133	A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). <i>Leukemia and Lymphoma</i> , 2011, 52, 394-399.	0.6	58

#	ARTICLE	IF	CITATIONS
134	Indolent Mantle-Cell Lymphoma: Immunoglobulin Variable Region Heavy Chain Sequence Analysis Reveals Evidence of Disease 10 Years Prior to Symptomatic Clinical Presentation. <i>Journal of Clinical Oncology</i> , 2011, 29, e437-e439.	0.8	13
135	Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2011, 29, 3023-3029.	0.8	66
136	Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. <i>Annals of Oncology</i> , 2012, 23, 1555-1561.	0.6	39
137	Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90â€Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. <i>Journal of Clinical Oncology</i> , 2012, 30, 3119-3126.	0.8	86
138	Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. <i>Haematologica</i> , 2012, 97, 579-585.	1.7	72
139	Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 552-560.	0.7	13
140	Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). <i>Annals of Oncology</i> , 2012, 23, 166-171.	0.6	53
141	Relapsed and/or Refractory Mantle cell Lymphoma: What Role for Temsirolimus?. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S7327.	0.6	4
142	Advances in the diagnosis and management of lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, , 29.	1.2	3
143	Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. <i>Blood</i> , 2012, 119, 4215-4223.	0.6	142
144	Autotransplantation for Mantle Cell Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 427-431.	1.0	4
145	Mantle Cell Lymphoma: A Clinically Heterogeneous Disease in Need of Tailored Approaches. <i>Cancer Control</i> , 2012, 19, 227-235.	0.7	40
146	SUV on Dual-Phase FDG PET/CT Correlates With the Ki-67 Proliferation Index in Patients With Newly Diagnosed Non-Hodgkin Lymphoma. <i>Clinical Nuclear Medicine</i> , 2012, 37, e189-e195.	0.7	24
147	Is ASCT With TBI Superior to ASCT Without TBI in Mantle Cell Lymphoma Patients?. <i>Transplantation</i> , 2012, 94, 295-301.	0.5	12
148	Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. <i>Blood</i> , 2012, 119, 2093-2099.	0.6	88
149	Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstr�m macroglobulinemia. <i>Blood</i> , 2012, 120, 3214-3221.	0.6	52
150	Guidelines for the investigation and management of mantle cell lymphoma. <i>British Journal of Haematology</i> , 2012, 159, 405-426.	1.2	72
151	Treatment of Older Patients with Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2012, 367, 520-531.	13.9	465

#	ARTICLE	IF	CITATIONS
152	Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated Patients. <i>Clinical Cancer Research</i> , 2012, 18, 6348-6355.	3.2	76
153	Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group. <i>Leukemia and Lymphoma</i> , 2012, 53, 1920-1928.	0.6	16
154	Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. <i>Blood</i> , 2012, 119, 4597-4607.	0.6	278
155	Diagnosis and management of rare gastrointestinal lymphomas. <i>Leukemia and Lymphoma</i> , 2012, 53, 2341-2350.	0.6	23
157	Hodgkin and Non-Hodgkin Lymphomas. , 2012, , 605-617.		0
158	Autologous transplantation and management of younger patients with mantle cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 211-220.	0.7	7
159	Management of mantle cell lymphoma in the elderly. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 221-231.	0.7	8
160	TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage. <i>Medical Oncology</i> , 2012, 29, 2166-2173.	1.2	11
161	Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study. <i>Medical Oncology</i> , 2012, 29, 2212-2219.	1.2	13
162	Two cases of mantle cell lymphoma mimicking marginal zone lymphoma. <i>Journal of Hematopathology</i> , 2012, 5, 335-340.	0.2	1
163	Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. <i>The Cochrane Library</i> , 2012, , CD009045.	1.5	5
164	Assessment of performance of survival prediction models for cancer prognosis. <i>BMC Medical Research Methodology</i> , 2012, 12, 102.	1.4	62
166	Mantle Cell Lymphoma: Decision Making for Transplant. , 2012, , .		0
167	Mantle cell lymphoma: 2012 update on diagnosis, risk stratification, and clinical management. <i>American Journal of Hematology</i> , 2012, 87, 604-609.	2.0	85
168	Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-CHyperCVAD. <i>Cancer</i> , 2012, 118, 3565-3570.	2.0	42
169	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. <i>British Journal of Haematology</i> , 2012, 156, 346-353.	1.2	122
170	Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. <i>Experimental Hematology</i> , 2012, 40, 359-366.	0.2	8
171	Mantle cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 78-101.	2.0	75

#	ARTICLE	IF	CITATIONS
172	Nordic <sc>MCL</sc>2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by <sc>BEAM</sc> or <sc>BEAC</sc>+autologous stem-cell support: still very long survival but late relapses do occur. <i>British Journal of Haematology</i> , 2012, 158, 355-362.	1.2	241
173	Mantle cell lymphoma presenting as a pelvi-ureteric junction obstruction: a case report. <i>Journal of Medical Case Reports</i> , 2013, 7, 105.	0.4	5
174	Actualit�s th�rapeutiques dans les lymphomes. , 2013, , .		0
175	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1475-1484.	2.0	28
176	The role of SOX11 in mantle cell lymphoma. <i>Leukemia Research</i> , 2013, 37, 1412-1419.	0.4	21
177	MicroRNAs in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1867-1875.	0.6	11
178	Risk factors of central nervous system relapse in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1908-1914.	0.6	38
180	Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: An investigation of clinical and histopathological features. <i>Acta Ophthalmologica</i> , 2013, 91, 1-27.	0.6	37
181	Management of Mantle Cell Lymphoma in the Elderly: Current and Potential Strategies. <i>Drugs and Aging</i> , 2013, 30, 979-986.	1.3	3
182	Open questions in the management of mantle cell lymphoma. <i>Cancer Treatment Reviews</i> , 2013, 39, 602-609.	3.4	9
183	Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management. <i>American Journal of Hematology</i> , 2013, 88, 1082-1088.	2.0	180
184	MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2903-2911.	0.8	37
185	High expression of cyclic nucleotide phosphodiesterase 7B mRNA predicts poor prognosis in mantle cell lymphoma. <i>Leukemia Research</i> , 2013, 37, 536-540.	0.4	7
186	Clinical Efficacy and Management of Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 351-359.	0.2	9
188	Using primary site as a predictor of survival in mantle cell lymphoma. <i>Cancer</i> , 2013, 119, 1570-1577.	2.0	33
189	Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1859-1861.	0.6	2
190	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2013, 24, 857-877.	0.6	268
191	Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 82-86.	2.0	6

#	ARTICLE	IF	CITATIONS
192	Specific Features Identify Patients with Relapsed or Refractory Mantle Cell Lymphoma Benefitting from Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1403-1406.	2.0	25
193	Rituximab-Induced Acute Severe Thrombocytopenia: A Case Series in Patients With Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 602-605.	0.2	14
194	Treatment for patients with indolent and mantle cell lymphoma. <i>Lancet, The</i> , 2013, 382, 1093-1094.	6.3	0
195	A Systematic Approach to the Diagnosis of Suspected Central Nervous System Lymphoma. <i>JAMA Neurology</i> , 2013, 70, 311.	4.5	143
196	Diagnosis and Treatment of Non-Hodgkin's Lymphoma of Adults. , 2013, , 1027-1047.		0
197	Whole genome profiling and other high throughput technologies in lymphoid neoplasms—current contributions and future hopes. <i>Modern Pathology</i> , 2013, 26, S97-S110.	2.9	17
198	Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop. <i>Leukemia and Lymphoma</i> , 2013, 54, 1882-1890.	0.6	9
199	Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital. <i>Leukemia and Lymphoma</i> , 2013, 54, 261-267.	0.6	35
200	Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. <i>Annals of Hematology</i> , 2013, 92, 1151-1179.	0.8	22
201	Current and Emerging Therapies in Mantle Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2013, 14, 198-211.	1.3	14
202	Mantle cell lymphoma: continuously improving the odds!. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 1001-1018.	0.5	0
203	Mantle Cell Lymphoma. , 2013, , 157-175.		0
205	Transplantation for mantle cell lymphoma: is it the right thing to do?. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 568-574.	0.9	14
206	Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2013, 48, 1212-1217.	1.3	28
207	Recent advances in the management of mantle cell lymphoma. <i>Current Opinion in Oncology</i> , 2013, 25, 716-721.	1.1	7
208	Primary Pancreatic Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 38-43.	0.6	29
209	Lymphome À cellules du manteau. , 2013, , 103-123.		0
210	Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. <i>Annals of Oncology</i> , 2013, 24, 2119-2123.	0.6	107

#	ARTICLE	IF	CITATIONS
211	Prognostic impact of monocyte count at presentation in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2013, 162, 465-473.	1.2	46
212	Immunohistochemical evaluation of <sc>MYC</sc> expression in mantle cell lymphoma. <i>Histopathology</i> , 2013, 63, 499-508.	1.6	28
213	A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. <i>Annals of Oncology</i> , 2013, 24, 1587-1593.	0.6	118
214	Cytarabine, Kiâ€67, and SOX11 in patients with mantle cell lymphoma receiving rituximabâ€containing autologous stem cell transplantation during first remission. <i>Cancer</i> , 2013, 119, 3318-3325.	2.0	5
215	Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?. <i>Bone Marrow Transplantation</i> , 2013, 48, 1489-1496.	1.3	8
216	Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3688-3695.	0.8	320
217	Survival of hematological patients after discharge from the intensive care unit: a prospective observational study. <i>Critical Care</i> , 2013, 17, R302.	2.5	16
218	Telomere length in mantle cell lymphoma. <i>Blood</i> , 2013, 121, 1184-1187.	0.6	19
219	Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. <i>Blood</i> , 2013, 122, 2412-2424.	0.6	185
220	First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. <i>Haematologica</i> , 2013, 98, 1563-1570.	1.7	25
222	Autologous stem cell transplantation for mantle cell lymphoma â€“ single centre experience. <i>Wspolczesna Onkologia</i> , 2013, 5, 456-459.	0.7	3
223	Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. <i>Cancer Management and Research</i> , 2013, 5, 225.	0.9	22
224	Hematopoietic cell transplantation for non-Hodgkin lymphoma. , 0, , 90-112.		0
225	Management of mantle cell lymphoma in the elderly patient. <i>Clinical Interventions in Aging</i> , 2013, 8, 1229.	1.3	11
226	Prognostic factors for lymphomas. , 0, , 11-31.		0
227	Mantle cell lymphoma. , 0, , 155-171.		0
228	What happened at EHA about mantle cell lymphoma?. <i>Hematologie</i> , 2014, 20, 142-152.	0.0	0
229	Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. <i>Blood Research</i> , 2014, 49, 15.	0.5	16

#	ARTICLE	IF	CITATIONS
230	Mantle cell lymphoma: a model for risk-adapted treatment approach. <i>Blood Research</i> , 2014, 49, 1.	0.5	2
231	Review Are we a step forward with targeted agents in resolving the enigma of mantle cell lymphoma?. <i>Wspolczesna Onkologia</i> , 2014, 6, 377-383.	0.7	1
232	Mantle Cell Lymphoma: Biology, Clinical Presentation, and Therapeutic Approaches. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 191-198.	1.8	30
233	Distinction between Asymptomatic Monoclonal B-cell Lymphocytosis with Cyclin D1 Overexpression and Mantle Cell Lymphoma: From Molecular Profiling to Flow Cytometry. <i>Clinical Cancer Research</i> , 2014, 20, 1007-1019.	3.2	44
234	Primary Gastrointestinal Mantle Cell Lymphoma: A Retrospective Study. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 481-486.	0.6	10
235	Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. <i>Leukemia and Lymphoma</i> , 2014, 55, 802-810.	0.6	28
236	Risk factors for etiology and prognosis of mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2014, 7, 233-243.	1.0	18
237	Management perspective for mantle cell lymphoma. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 31-40.	0.7	0
238	Mantle Cell Lymphoma. , 2014, , 1687-1700.		0
239	Prognostic Significance of Serum Beta-2 Microglobulin in Patients with Non-Hodgkin Lymphoma. <i>Oncology</i> , 2014, 87, 40-47.	0.9	14
240	SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study. <i>British Journal of Haematology</i> , 2014, 166, 98-108.	1.2	110
241	Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 106-116.	1.5	57
242	Prognostic impact of monocyte count at presentation in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2014, 164, 890-893.	1.2	9
243	Effect of Radiotherapy on the Survival of Patients With Stage I and Stage II Mantle Cell Lymphoma: Analysis of the Surveillance, Epidemiology and End Results Database. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S90-S95.	0.2	14
244	T-Cell Levels Are Prognostic in Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 6096-6104.	3.2	33
245	Role of ibrutinib for the treatment of mantle cell lymphoma in the elderly. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 53-61.	0.7	0
246	Bortezomib for the treatment of mantle cell lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 1233-1241.	0.5	1
247	Indolent mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 761-767.	0.6	33

#	ARTICLE	IF	CITATIONS
248	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii83-iii92.	0.6	129
249	Consolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspective. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 153-167.	1.1	9
250	Hematopoietic Cell Transplantation for Mantle Cell Lymphoma: Predictive Value of Pretransplant Positron Emission Tomography/Computed Tomography and Bone Marrow Evaluations for Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 114-121.	0.2	20
251	Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. <i>Leukemia and Lymphoma</i> , 2014, 55, 988-998.	0.6	10
252	Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. <i>Annals of Hematology</i> , 2014, 93, 803-810.	0.8	6
253	Decision Tools for Radiation Oncology. <i>Medical Radiology</i> , 2014, , .	0.0	2
254	Current role of FDG PET/CT in lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1004-1027.	3.3	63
255	Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 1586-1594.	0.8	87
256	Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy- β -D-glucoseâ€“positron emission tomography/computed tomography in mantle cell lymphoma?. <i>Leukemia and Lymphoma</i> , 2014, 55, 2484-2489.	0.6	23
257	Radiation Therapy Is an Effective Modality in the Treatment of Mantle Cell Lymphoma, Even in Heavily Pretreated Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 474-479.	0.2	20
258	Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. <i>Journal of Clinical Oncology</i> , 2014, 32, 3059-3067.	0.8	3,729
259	Current regimens and novel agents for mantle cell lymphoma. <i>British Journal of Haematology</i> , 2014, 167, 3-18.	1.2	16
260	High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial. <i>Leukemia and Lymphoma</i> , 2014, 55, 1206-1208.	0.6	18
261	How to manage mantle cell lymphoma. <i>Leukemia</i> , 2014, 28, 2117-2130.	3.3	44
262	Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages. <i>Hematological Oncology</i> , 2014, 32, 178-186.	0.8	32
263	New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?. <i>Clinical Cancer Research</i> , 2014, 20, 5194-5206.	3.2	31
264	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3048-3058.	0.8	1,269
265	Mantle cell lymphoma epidemiology: a population-based study in France. <i>Annals of Hematology</i> , 2014, 93, 1327-1333.	0.8	29

#	ARTICLE	IF	CITATIONS
266	Allogeneic stem cell transplantation for mantle cell lymphoma—final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). <i>Annals of Hematology</i> , 2014, 93, 1587-1597.	0.8	52
267	A phase 1 study of the PI3K γ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). <i>Blood</i> , 2014, 123, 3398-3405.	0.6	245
268	Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2014, 32, 1338-1346.	0.8	137
269	Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 587-597.	1.4	11
270	Is Early Hematopoietic Stem-Cell Transplantation Necessary in Mantle-Cell Lymphoma?. <i>Journal of Clinical Oncology</i> , 2014, 32, 265-267.	0.8	6
271	Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 50-55.	0.2	28
272	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. <i>Annals of Hematology</i> , 2014, 93, 233-242.	0.8	17
273	Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. <i>Blood</i> , 2014, 124, 1288-1295.	0.6	113
274	Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. <i>Blood</i> , 2014, 123, 2953-2959.	0.6	90
275	Emerging Therapy for the Treatment of Mantle Cell Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1311-1318.	2.3	5
276	Updated survival analysis of two sequential prospective trials of R α CMA20 followed by maintenance for newly diagnosed mantle cell lymphoma. <i>American Journal of Hematology</i> , 2015, 90, E111-6.	2.0	6
277	Mantle cell lymphoma: 2015 update on diagnosis, risk stratification, and clinical management. <i>American Journal of Hematology</i> , 2015, 90, 739-745.	2.0	83
278	Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review. <i>Cancer Medicine</i> , 2015, 4, 1817-1827.	1.3	2
279	Mantle cell lymphoma: evolving management strategies. <i>Blood</i> , 2015, 125, 48-55.	0.6	155
280	Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience. <i>Haematologica</i> , 2015, 100, 706-708.	1.7	5
281	A balanced hazard ratio for risk group evaluation from survival data. <i>Statistics in Medicine</i> , 2015, 34, 2528-2543.	0.8	2
282	Synchronous Pulmonary Malignancies: Atypical Presentation of Mantle Cell Lymphoma Masking a Lung Malignancy. <i>Rare Tumors</i> , 2015, 7, 114-116.	0.3	5
283	Longer-term follow-up and outcome by tumour cell proliferation rate (Ki67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL001(EMERGE) pivotal trial. <i>British Journal of Haematology</i> , 2015, 170, 496-503.	1.2	34

#	ARTICLE	IF	CITATIONS
284	Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan. <i>British Journal of Haematology</i> , 2015, 170, 657-668.	1.2	20
285	High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 788-797.	1.2	11
286	Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma. <i>Histopathology</i> , 2015, 67, 62-69.	1.6	12
287	Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1663.	0.9	1
288	Real Benefit of Anthracycline-Based Chemotherapy in Elderly and Impaired Patients: a Retrospective Analysis. <i>Journal of Integrative Oncology</i> , 2015, 04, .	0.3	0
289	Emerging role of SOX11 in mantle cell lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2015, , 35.	1.2	0
290	Oxidative DNA Damage, Oxidative Stress and Genetic Susceptibility-Prognostic Scores in "Missing" COPD Cases. <i>International Journal of Human Genetics</i> , 2015, 15, 97-119.	0.1	1
291	Allogeneic Hematopoietic Stem Cell Transplantation in Mantle Cell Lymphoma: A Retrospective Analysis of 7 Patients. <i>Oncology</i> , 2015, 89, 118-123.	0.9	0
292	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. <i>Blood</i> , 2015, 126, 604-611.	0.6	130
293	Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis. <i>Experimental Hematology and Oncology</i> , 2015, 4, 11.	2.0	6
294	Mantle cell lymphoma: Towards a personalized therapeutic strategy?. <i>Medicina Clínica (English)</i> Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50 3	0.1	0
295	Mantle cell lymphoma: observation to transplantation. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 37-48.	1.1	19
296	Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL). <i>Annals of Oncology</i> , 2015, 26, 966-973.	0.6	37
297	<scp>TCL</scp> 1 expression predicts overall survival in patients with mantle cell lymphoma. <i>European Journal of Haematology</i> , 2015, 95, 583-594.	1.1	8
298	Pericardial, pleural and peritoneal involvement in a patient with primary gastric mantle cell lymphoma. <i>Scottish Medical Journal</i> , 2015, 60, e21-e24.	0.7	4
299	Lenalidomide for mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2015, 8, 257-264.	1.0	5
300	Imaging of Non-Hodgkin Lymphomas: Diagnosis and Response-Adapted Strategies. <i>Cancer Treatment and Research</i> , 2015, 165, 125-146.	0.2	12
301	Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 848-854.	2.0	40

#	ARTICLE	IF	CITATIONS
302	Prognosis and outcome of stem cell transplantation for mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2015, 8, 493-504.	1.0	2
303	Next-generation surveillance strategies for patients with lymphoma. <i>Future Oncology</i> , 2015, 11, 1977-1991.	1.1	15
304	Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice. <i>Clinical Cancer Research</i> , 2015, 21, 3853-3861.	3.2	20
305	Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 278-285.e1.	0.2	19
307	Resultados del tratamiento del linfoma de células del manto con varios regímenes de inmunoterapia: estudio retrospectivo. <i>Revista Colombiana De Cancerología</i> , 2015, 19, 71-80.	0.0	0
308	Pathology of B-Cell Lymphomas: Diagnosis and Biomarker Discovery. <i>Cancer Treatment and Research</i> , 2015, 165, 27-50.	0.2	10
309	Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation. <i>Current Treatment Options in Oncology</i> , 2015, 16, 29.	1.3	2
310	Treatment Strategies in Mantle Cell Lymphoma. <i>Cancer Treatment and Research</i> , 2015, 165, 251-270.	0.2	9
311	Lymphoma in older patients: clinical and therapeutic characteristics. <i>Reviews in Clinical Gerontology</i> , 2015, 25, 1-11.	0.5	0
312	Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 944-953.	13.9	343
314	Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study. <i>Annals of Oncology</i> , 2015, 26, 2311-2317.	0.6	22
315	No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo. <i>Leukemia and Lymphoma</i> , 2015, 56, 2134-2140.	0.6	2
316	Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era. <i>British Journal of Haematology</i> , 2015, 168, 708-718.	1.2	29
317	Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. <i>Annals of Oncology</i> , 2015, 26, 2323-2328.	0.6	30
318	Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. <i>Bone Marrow Transplantation</i> , 2015, 50, 1293-1298.	1.3	15
319	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. <i>Journal of Clinical Oncology</i> , 2015, 33, 3766-3773.	0.8	328
320	Management Trends and Outcomes for Stage I to II Mantle Cell Lymphoma Using the National Cancer Data Base: Ascertaining the Ideal Treatment Paradigm. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 668-676.	0.4	11
321	Next-generation prognostic assessment for diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2015, 11, 2443-2457.	1.1	8

#	ARTICLE	IF	CITATIONS
322	FDG-PET(CT)-adapted trials in non-Hodgkin lymphoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 295-307.	1.1	3
323	FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 271-281.	1.1	2
324	Treatment options for mantle cell lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2497-2507.	0.9	9
325	The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 115-124.	0.8	184
326	High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma. <i>Current Oncology Reports</i> , 2015, 17, 42.	1.8	13
327	Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1425-1431.	0.6	19
329	The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. <i>Leukemia</i> , 2015, 29, 464-473.	3.3	64
330	PARP1 expression in mantle cell lymphoma: the utility of PARP1 immunohistochemistry and its relationship with markers of DNA damage. <i>Hematological Oncology</i> , 2015, 33, 159-165.	0.8	4
331	Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 383-389.	0.6	7
332	Role of allogeneic stem cell transplantation in mantle cell lymphoma. <i>European Journal of Haematology</i> , 2015, 94, 290-297.	1.1	11
333	Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents. <i>Oncotarget</i> , 2016, 7, 48692-48731.	0.8	51
334	Prognostic relevance of the Ki-67 proliferation index in patients with mantle cell lymphoma. <i>Blood Research</i> , 2016, 51, 127.	0.5	11
335	The Danish National Lymphoma Registry: Coverage and Data Quality. <i>PLoS ONE</i> , 2016, 11, e0157999.	1.1	66
336	Phase II trial of CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. <i>British Journal of Haematology</i> , 2016, 172, 208-218.	1.2	45
337	Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. <i>Blood</i> , 2016, 128, 1814-1820.	0.6	75
338	The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma. <i>BMC Cancer</i> , 2016, 16, 802.	1.1	7
339	Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma. <i>BMC Cancer</i> , 2016, 16, 598.	1.1	6
340	Negative prognostic impact of low absolute CD4 ⁺ T cell counts in peripheral blood in mantle cell lymphoma. <i>Cancer Science</i> , 2016, 107, 1471-1476.	1.7	27

#	ARTICLE	IF	CITATIONS
341	LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2. <i>Journal of Translational Medicine</i> , 2016, 14, 346.	1.8	86
342	Treatment of the elderly patient with mantle cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 425-431.	0.9	6
343	Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 432-436.	0.9	3
344	Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 437-445.	0.9	37
345	PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 24.	1.3	19
347	Bortezomib for the treatment of mantle cell lymphoma: an update. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 196-208.	1.1	39
348	Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2016, 34, 1386-1394.	0.8	276
349	FDG-PET imaging in hematological malignancies. <i>Blood Reviews</i> , 2016, 30, 317-331.	2.8	43
350	Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 234-240.	1.2	8
351	An update on ocular adnexal lymphoma. <i>Seminars in Diagnostic Pathology</i> , 2016, 33, 164-172.	1.0	9
352	Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. <i>Bone Marrow Transplantation</i> , 2016, 51, 1184-1190.	1.3	31
353	Validation of cutaneous lymphoma international prognostic index (CLUPI) for mycosis fungoides and SÅ©zary syndrome. <i>Leukemia and Lymphoma</i> , 2016, 57, 2813-2819.	0.6	16
354	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1543-1551.	2.0	42
355	Mantle cell lymphoma, response to treatment and prognosis in 45 patients. <i>Medicina Clínica (English)</i> Tj ETQq1 1 0,784314 rgBT /Over	0.1	0
357	Rituximab plus hyperâ€œ<sc>CVAD</sc> alternating with <sc>MTX</sc>/Araâ€œ in patients with newly diagnosed mantle cell lymphoma: 15â€œyear followâ€œup of a phase <sc>II</sc> study from the <sc>MD</sc> Anderson Cancer Center. <i>British Journal of Haematology</i> , 2016, 172, 80-88.	1.2	82
358	Identification of miR-15b as a transformation-related factor in mantle cell lymphoma. <i>International Journal of Oncology</i> , 2016, 48, 485-492.	1.4	21
359	Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1345-1370.	0.9	5
360	A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 471-476.	1.4	3

#	ARTICLE	IF	CITATIONS
361	Small Intestinal Cancers. , 2016, , 519-553.		0
362	The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. <i>Haematologica</i> , 2016, 101, 235-240.	1.7	24
363	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i> , The, 2016, 388, 565-575.	6.3	328
364	Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. <i>Cancer</i> , 2016, 122, 2356-2363.	2.0	51
365	Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma. <i>Hematological Oncology</i> , 2016, 34, 22-27.	0.8	25
366	A phase 2 study of Rituximab+ Bendamustine and Rituximab+ Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 89-95.	1.2	51
367	Efficacy of the GemOx+R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma. <i>British Journal of Haematology</i> , 2016, 174, 899-910.	1.2	13
368	Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2016, 387, 770-778.	6.3	389
369	Will new drugs change the standard of care for patients with mantle cell lymphoma?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 199-210.	1.1	1
370	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002); Tj ETQq1 1 0.784314 rgBT /Overbo	5.1	135
371	Recommendations to stage and assess the response to therapy of lymphomas with [18F]FDG-PET-CT. <i>Medecine Nucleaire</i> , 2016, 40, 55-64.	0.2	2
372	The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?. <i>Haematologica</i> , 2016, 101, 104-114.	1.7	31
373	Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. <i>Bone Marrow Transplantation</i> , 2016, 51, 654-662.	1.3	9
374	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	1.7	67
375	Mantle cell lymphoma with multiple lymphomatous polyposis and intussusception: A case report. <i>Oncology Letters</i> , 2016, 11, 654-656.	0.8	3
376	Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1256-1269.	0.8	247
377	Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies. <i>Journal of Biological Chemistry</i> , 2016, 291, 3268-3279.	1.6	75
378	Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 175-189.	1.0	7

#	ARTICLE	IF	CITATIONS
379	Non-Hodgkin's Lymphoma. , 2016, , 1524-1546.e7.		2
380	Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. <i>Leukemia</i> , 2016, 30, 1428-1430.	3.3	19
381	Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 380-385.	2.0	37
382	Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis. <i>Leukemia and Lymphoma</i> , 2016, 57, 676-684.	0.6	8
383	Mantle cell lymphomaâ€”a spectrum from indolent to aggressive disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 245-257.	1.4	65
384	PÃ³lipo Ãºnico colÃ³nico como forma de presentaciÃ³n de linfoma del manto. <i>GastroenterologÃa Y HepatologÃa</i> , 2017, 40, 682-684.	0.2	0
385	Non-Hodgkin lymphoma. <i>Lancet, The</i> , 2017, 390, 298-310.	6.3	615
387	Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement. <i>BMC Cancer</i> , 2017, 17, 128.	1.1	7
388	Results from the Belgian mantle cell lymphoma registry. <i>Acta Clinica Belgica</i> , 2017, 72, 172-178.	0.5	3
389	Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP <i>versus</i> R-CHOP in the phase 3 LYM-3002 study. <i>Haematologica</i> , 2017, 102, 895-902.	1.7	6
391	Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 99-115.	0.6	14
393	Mantle Cell Lymphoma With MYC Rearrangement. <i>American Journal of Surgical Pathology</i> , 2017, 41, 216-224.	2.1	48
394	Mantle cell lymphoma â€œ Current standards of care and future directions. <i>Cancer Treatment Reviews</i> , 2017, 58, 51-60.	3.4	12
396	Current Status of Brutonâ€™s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. <i>Drugs and Aging</i> , 2017, 34, 509-527.	1.3	34
397	Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. <i>Blood</i> , 2017, 130, 39-47.	0.6	43
398	Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. <i>Leukemia and Lymphoma</i> , 2017, 58, 2824-2832.	0.6	15
399	Evolution of lymphoma staging and response evaluation: current limitations and future directions. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 631-645.	12.5	26
400	Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?. <i>Bone Marrow Transplantation</i> , 2017, 52, 1487-1494.	1.3	17

#	ARTICLE	IF	CITATIONS
401	Mantle cell lymphoma presenting as multiple lymphomatous polyposis of the gastrointestinal tract. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 73-76.	0.7	10
402	B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood, 2017, 129, 333-346.	0.6	57
403	Pleomorphic mantle cell lymphoma morphologically mimicking diffuse large B cell lymphoma: common cyclin D1 negativity and a simple immunohistochemical algorithm to avoid the diagnostic pitfall. Histopathology, 2017, 70, 986-999.	1.6	18
404	Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. Journal of the National Cancer Institute, 2017, 109, djw263.	3.0	10
405	Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and Tj ETQq0 0 0 rBT /Overlock 10 Tf 428-435.	2.0	56
406	<sc>RB</sc> but not Râ€«sc>HCVAD</sc> is a feasible induction regimen prior to autoâ€«sc>HCT</sc> in frontline <sc>MCL</sc>: results of <sc>SWOG</sc> Study S1106. British Journal of Haematology, 2017, 176, 759-769.	1.2	40
407	Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?. International Journal of Hematology, 2017, 105, 257-264.	0.7	9
408	Data quality improvement of a multicenter clinical trial dataset. , 2017, 2017, 1190-1193.		6
409	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy, 2017, 34, 2232-2273.	1.3	407
410	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. New England Journal of Medicine, 2017, 377, 1250-1260.	13.9	313
411	The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-Î®B mutational status. Haematologica, 2017, 102, e447-e451.	1.7	18
412	18 F-FDG PET/CT in the clinical management of patients with lymphoma. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2017, 36, 312-321.	0.1	3
413	Orbital mantle cell lymphoma presenting as myasthenia gravis. Orbit, 2017, 36, 365-369.	0.5	10
414	Radiation Therapy in Mantle Cell Lymphoma. , 2017, , 1-14.		0
415	Non-Hodgkin Lymphoma â€« State of the Art and Next Questions. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S160-S164.	0.2	0
416	A MALT lymphoma prognostic index. Blood, 2017, 130, 1409-1417.	0.6	149
417	Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. American Journal of Hematology, 2017, 92, E575-E583.	2.0	17
418	Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. American Journal of Hematology, 2017, 92, 806-813.	2.0	149

#	ARTICLE	IF	CITATIONS
419	18 F-FDG PET/TC en el manejo cl�nico de los linfomas. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2017, 36, 312-321.	0.0	3
420	CD5-negative mantle cell lymphoma shows a less aggressive outcome and variable SOX11 staining. Journal of Hematopathology, 2017, 10, 49-53.	0.2	4
421	Current and emerging treatment options for mantle cell lymphoma. Therapeutic Advances in Hematology, 2017, 8, 223-234.	1.1	20
422	Mantle-Cell Lymphoma�Taming the Tiger. JAMA Ophthalmology, 2017, 135, 1374.	1.4	1
423	Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). Annals of Oncology, 2017, 28, 2185-2190.	0.6	26
424	Radiation Therapy in Hematologic Malignancies. , 2017, , .		0
425	Validation of R��MIPI and prognostic value of immunoglobulin light chain restriction in mantle cell lymphoma. British Journal of Haematology, 2017, 177, 816-818.	1.2	0
426	Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. Leukemia and Lymphoma, 2017, 58, 623-632.	0.6	5
427	Unsuspected Malignancies in Routine Femoral Head Histopathologic Examination During Primary Total Hip Arthroplasty: Cost-Effectiveness Analysis. Journal of Arthroplasty, 2017, 32, 735-742.	1.5	12
428	Bilateral ocular panadnexal mass as initial presentation of systemic blastoid variant of mantle-cell lymphoma. Survey of Ophthalmology, 2017, 62, 83-88.	1.7	6
429	Single colonic polyp as a presentation of mantle cell lymphoma. Gastroenterolog� Y Hepatolog� (English Edition), 2017, 40, 682-684.	0.0	0
430	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2017, 28, iv62-iv71.	0.6	387
431	Asymptomatic Multiple Lymphomatous Polyposis Identified during Staging Bidirectional Endoscopy of Mantle Cell Lymphoma. Case Reports in Oncology, 2017, 9, 661-665.	0.3	0
432	Hematopoietic cell transplants for Hodgkin lymphoma. , 0, , 361-371.		0
433	Hematopoietic cell transplants for mantle cell lymphoma. , 0, , 402-416.		0
434	Management of relapsed and refractory mantle cell lymphoma: a review of current evidence and future directions for research. Annals of Lymphoma, 0, 1, 1-1.	4.5	0
435	Age and Sex in Non-Hodgkin Lymphoma Therapy: It��s Not All Created Equal, or Is It?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 505-511.	1.8	23
436	Mantle Cell Lymphoma in the Thyroid: A Rare Presentation. Case Reports in Pathology, 2017, 2017, 1-6.	0.2	4

#	ARTICLE	IF	CITATIONS
437	The role of B cell antigen receptors in mantle cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 164.	6.9	17
438	Smoldering mantle cell lymphoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 185.	3.5	31
439	Mantle cell lymphoma: primary oral presentation. <i>Annals of the Royal College of Surgeons of England</i> , 2017, 99, e13-e14.	0.3	4
440	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <i>Journal of Clinical Oncology</i> , 2017, 35, 1668-1677.	0.8	102
441	Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 512-525.	1.8	16
442	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <i>Haematologica</i> , 2018, 103, 849-856.	1.7	21
443	Mantle Cell Lymphoma—Time to Dismantle the Treatment Paradox. <i>JAMA Oncology</i> , 2018, 4, 626.	3.4	2
445	Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 343-353.	0.1	1
446	Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2018, 181, 495-504.	1.2	21
447	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018, 124, 2306-2315.	2.0	40
448	Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma. <i>Annals of Hematology</i> , 2018, 97, 1445-1452.	0.8	7
450	Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma. <i>Experimental Hematology</i> , 2018, 59, 72-81.e2.	0.2	9
451	Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. <i>Bone Marrow Transplantation</i> , 2018, 53, 461-473.	1.3	28
452	Treatment of mantle cell lymphoma in older adults. <i>Journal of Geriatric Oncology</i> , 2018, 9, 308-314.	0.5	4
453	The First Case of Lupus Nephritis Developing in a Patient With Mantle Cell Lymphoma. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 159-164.	0.5	3
454	Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN). <i>British Journal of Haematology</i> , 2018, 181, 215-228.	1.2	36
455	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1211-1223.	13.9	343
456	The degree of overlap between the follicular dendritic cell meshwork and tumor cells in mantle cell lymphoma is associated with prognosis. <i>Pathology Research and Practice</i> , 2018, 214, 513-520.	1.0	3

#	ARTICLE	IF	CITATIONS
457	Linfomatosis menÁngea tardÁa en linfoma del manto controlada con quimioterapia. NeurologÁa, 2018, 33, 201-202.	0.3	0
458	Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience. Hematological Oncology, 2018, 36, 116-120.	0.8	5
459	Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 282-287.	2.0	8
460	PET/CT for Staging; Past, Present, and Future. Seminars in Nuclear Medicine, 2018, 48, 4-16.	2.5	48
461	CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Modern Pathology, 2018, 31, 327-336.	2.9	46
462	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leukemia and Lymphoma, 2018, 59, 1814-1828.	0.6	23
463	Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood, 2018, 131, 417-420.	0.6	108
464	Prospective subgroup analyses of the randomized <scp>MCL</scp>â€002 (<scp>SPRINT</scp>) study: lenalidomide <i>versus</i> investigator's choice in relapsed or refractory mantle cell lymphoma. British Journal of Haematology, 2018, 180, 224-235.	1.2	10
465	PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up. Seminars in Nuclear Medicine, 2018, 48, 37-49.	2.5	28
466	R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20Âyears of single-center experience. Annals of Hematology, 2018, 97, 277-287.	0.8	11
467	Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma. Leukemia and Lymphoma, 2018, 59, 670-678.	0.6	8
468	Risk stratification of mantle cell lymphoma (MCL). Annals of Lymphoma, 0, 2, 10-10.	4.5	5
469	Epidemiological Analysis of Lymphoma Subtypes in a Reference Center in JoÃ£o Pessoa. International Journal of Physical Medicine & Rehabilitation, 2018, 06, .	0.5	2
470	Rituximab Maintenance Therapy and Bendamustine Containing Treatments may improve the Survival of Mantle Cell Lymphoma: Retrospective Analysis in Single Institute. Journal of Blood & Lymph, 2018, 08, .	0.0	0
471	Gastrointestinal Perforation after Rituximab Therapy in Mantle Cell Lymphoma: A Case Report. Case Reports in Oncology, 2018, 11, 784-790.	0.3	4
472	Non-Hodgkinâ€™s Lymphoma. , 2018, , 757-768.		0
473	Genomic landscape and prognostic analysis of mantle cell lymphoma. Cancer Gene Therapy, 2018, 25, 129-140.	2.2	49
474	Diagnosis and Treatment of Non-Hodgkinâ€™s Lymphoma of Adults. , 2018, , 951-973.		0

#	ARTICLE	IF	CITATIONS
475	Râ€Highâ€<scp>CHOP</scp>/<scp>CHASER</scp>/<scp>LEED</scp> with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. Cancer Science, 2018, 109, 2830-2840.	1.7	14
476	The <scp>MCL</scp>35 gene expression proliferation assay predicts highâ€risk <scp>MCL</scp> patients in a Norwegian cohort of younger patients given intensive first line therapy. British Journal of Haematology, 2018, 183, 225-234.	1.2	24
477	Recent advances in treating extra-ocular lymphomas. Expert Review of Ophthalmology, 2018, 13, 205-217.	0.3	12
478	Mantle Cell Lymphoma. , 2018, , 1298-1308.e2.		1
479	History of autoimmune conditions and lymphoma prognosis. Blood Cancer Journal, 2018, 8, 73.	2.8	26
480	Evolving treatment strategies in mantle cell lymphoma. Best Practice and Research in Clinical Haematology, 2018, 31, 270-278.	0.7	6
481	Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma. Current Oncology Reports, 2018, 20, 79.	1.8	11
482	Late-onset meningeal lymphomatosis in mantle cell lymphoma controlled with chemotherapy. NeurologÅa (English Edition), 2018, 33, 201-202.	0.2	0
483	TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 762-768.	0.2	23
484	Update on mantle cell lymphoma. Blood, 2018, 132, 1647-1656.	0.6	144
485	A British Society for haematology good practice paper on the diagnosis and investigation of patients with mantle cell lymphoma. British Journal of Haematology, 2018, 182, 63-70.	1.2	11
486	Immunophenotypic Variations in Mantle Cell Lymphoma and Their Impact on Clinical Behavior and Outcome. Archives of Pathology and Laboratory Medicine, 2018, 142, 1268-1274.	1.2	7
487	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Leukemia and Lymphoma, 2018, 59, 2862-2870.	0.6	13
488	Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials. Leukemia and Lymphoma, 2018, 59, 2769-2781.	0.6	14
489	Validation of the <scp>MCL</scp>35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. British Journal of Haematology, 2019, 184, 616-624.	1.2	25
490	The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice. Frontiers in Oncology, 2019, 9, 528.	1.3	27
491	Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2760-2769.	3.3	55
492	Allogenic Transplant for Non-Hodgkin Lymphoma. , 2019, , 209-229.		0

#	ARTICLE	IF	CITATIONS
493	A Rare Manifestation of a Rare Disease: Mantle Cell Lymphoma Presenting With Aseptic Meningitis. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2019, 7, 232470961985864.	0.3	0
494	Optimal management of mantle cell lymphoma in the primary setting. <i>Expert Review of Hematology</i> , 2019, 12, 715-721.	1.0	0
496	Practical Head and Neck Pathology. , 2019, , .		0
497	Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. <i>Cancer Medicine</i> , 2019, 8, 6860-6870.	1.3	22
498	Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1957-1961.	0.2	3
499	Downregulation of MANCR inhibits cancer cell proliferation in mantle cell lymphoma possibly by interacting with RUNX2. <i>Acta Biochimica Et Biophysica Sinica</i> , 2019, 51, 1142-1147.	0.9	16
500	Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. <i>Human Pathology</i> , 2019, 93, 54-64.	1.1	8
501	Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4417.	1.8	23
502	Dysregulation of N6-methyladenosine regulators predicts poor patient survival in mantle cell lymphoma. <i>Oncology Letters</i> , 2019, 18, 3682-3690.	0.8	13
506	Gastrointestinal Involvement in Patients with Mantle Cell Lymphoma: A Single Center Experience of Eighty-Five Patients. <i>Digestive Diseases</i> , 2019, 37, 194-200.	0.8	9
507	Mantle Cell Lymphoma: Which Patients Should We Transplant?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 239-246.	1.2	6
508	Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls. <i>British Journal of Haematology</i> , 2019, 186, 409-419.	1.2	7
509	Mantle Cell Lymphoma With Mantle Zone Growth Pattern. <i>American Journal of Clinical Pathology</i> , 2019, 152, 132-145.	0.4	3
510	A revised international prognostic score system for Waldenström's macroglobulinemia. <i>Leukemia</i> , 2019, 33, 2654-2661.	3.3	53
511	Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. <i>Blood Cancer Journal</i> , 2019, 9, 50.	2.8	75
512	CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis. <i>Human Pathology</i> , 2019, 89, 71-80.	1.1	23
513	Review of Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. <i>Current Oncology</i> , 2019, 26, 233-240.	0.9	66
514	Diagnostic and Clinical Impact of Staging 18F-FDG PET/CT in Mantle-Cell Lymphoma: A Two-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e457-e464.	0.2	11

#	ARTICLE	IF	CITATIONS
515	CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Therapeutic Advances in Hematology, 2019, 10, 204062071984158.	1.1	160
517	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in nonâ€ƒfollicular indolent Bâ€ƒcell lymphomas. American Journal of Hematology, 2019, 94, 658-666.	2.0	19
518	Mantle cell lymphoma presenting with exaggerated skin reaction to insect bites. BMJ Case Reports, 2019, 12, e227590.	0.2	4
520	Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. American Journal of Hematology, 2019, 94, 710-725.	2.0	151
521	Interest of FDG-PET in the Management of Mantle Cell Lymphoma. Frontiers in Medicine, 2019, 6, 70.	1.2	13
522	Association of red blood cell distribution width and outcomes in patients with mantle cell lymphoma. Cancer Medicine, 2019, 8, 2751-2758.	1.3	9
523	Acalabrutinib for mantle cell lymphoma. Blood, 2019, 133, 2570-2574.	0.6	19
524	Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. Journal of Clinical Oncology, 2019, 37, 471-480.	0.8	74
525	Turning Point in the Treatment of Mantle Cell Lymphoma. Yonago Acta Medica, 2019, 62, 001-007.	0.3	1
526	Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma. Annals of Nuclear Medicine, 2019, 33, 449-458.	1.2	48
527	Low absolute NK cell counts in peripheral blood are associated with inferior survival in patients with mantle cell lymphoma. Cancer Biomarkers, 2019, 24, 439-447.	0.8	7
528	Le urgenze ematologiche. Italian Journal of Medicine, 2019, , 1-100.	0.2	0
529	Mantle cell lymphoma and its management: where are we now?. Experimental Hematology and Oncology, 2019, 8, 2.	2.0	28
530	Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes. JCO Clinical Cancer Informatics, 2019, 3, 1-15.	1.0	7
531	The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study. Cancers, 2019, 11, 1831.	1.7	18
532	Can the prognosis of mantle cell lymphoma be predicted by simple CBC counts?. Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlo	0.4	4
533	Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation. Current Opinion in Oncology, 2019, 31, 374-379.	1.1	4
534	SOX11-negative Mantle Cell Lymphoma. American Journal of Surgical Pathology, 2019, 43, 710-716.	2.1	22

#	ARTICLE	IF	CITATIONS
535	Simplified MIPI-B prognostic stratification method can predict the outcome wellâ€”retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China. <i>Medicine (United States)</i> , 2019, 98, e13741.	0.4	5
536	CD5-negative Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1052-1060.	2.1	25
537	Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry^{â€‹}. <i>Leukemia and Lymphoma</i> , 2019, 60, 748-755.	0.6	7
538	A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. <i>Haematologica</i> , 2019, 104, 138-146.	1.7	37
539	Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 48-52.	0.2	1
540	Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas. <i>Leukemia and Lymphoma</i> , 2019, 60, 1580-1583.	0.6	6
541	Accuracy of diagnosing mantle cell lymphoma and identifying its variants on fineâ€”needle aspiration biopsy. <i>Cancer Cytopathology</i> , 2019, 127, 44-51.	1.4	10
542	Lenalidomide for the treatment of mantle cell lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 487-494.	0.9	19
543	Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0210224.	1.1	71
544	Validation of the Marginal Zone Lymphoma International Prognostic Index. <i>Annals of Hematology</i> , 2019, 98, 457-464.	0.8	11
545	Nomogram incorporating clinicopathological parameters to predict the survival of patients with mantle cell lymphoma. <i>Journal of Investigative Medicine</i> , 2019, 67, 331-337.	0.7	2
546	<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , 2020, 105, 1604-1612.	1.7	96
547	Non-indolent mantle cell lymphoma at a single public hospital in Brazil: real world first-line treatment cohort study data. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 93-97.	0.1	1
548	Subtype Distribution, Clinical Features, and Survival in B-cell Chronic Lymphoproliferative Disorders in China: A Review of 1592 Cases. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e270-e283.	0.2	7
549	Comorbidities and sex differences in causes of death among mantle cell lymphoma patients â€” A nationwide populationâ€”based cohort study. <i>British Journal of Haematology</i> , 2020, 189, 106-116.	1.2	13
550	Non-Hodgkin Lymphomas. , 2020, , 1926-1947.e5.		0
551	Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinibâ€”resistant nonâ€”nodal leukemic mantle cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 352-355.	1.1	6
552	Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report. <i>Annals of Hematology</i> , 2020, 99, 223-228.	0.8	6

#	ARTICLE	IF	CITATIONS
553	Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP. <i>British Journal of Haematology</i> , 2020, 188, 860-871.	1.2	5
554	An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 29-38.	0.9	3
555	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 248-256.	0.8	73
556	Using the primary site as a prognostic tool for nodal mantle cell lymphoma: a SEER-based study. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 861-876.	0.6	2
557	Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study. <i>Annals of Translational Medicine</i> , 2020, 8, 1048-1048.	0.7	5
558	High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management. <i>Journal of Clinical Oncology</i> , 2020, 38, 4302-4316.	0.8	22
559	Mantle cell lymphoma of palatine tonsil: A case report. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101218.	0.2	0
560	Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 957-970.	0.9	6
561	Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 983-996.	0.9	0
562	Linfomas. <i>Medicine</i> , 2020, 13, 1125-1132.	0.0	0
563	Recent advances in the first-line treatment of mantle cell lymphoma. <i>Annals of Lymphoma</i> , 0, 4, 2-2.	4.5	4
564	Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy. <i>Cancers</i> , 2020, 12, 2120.	1.7	24
565	Watch and Wait in Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 837-847.	0.9	4
566	¹⁸ F-FDG PET or PET/CT in Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 422-430.	0.2	17
568	Advances in Classification and Treatment of Non-Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 348-356.	1.0	2
569	Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6573-6581.	1.0	10
570	High viral loads of circulating Epstein-Barr virus DNA copy number in peripheral blood is associated with inferior prognosis in patients with mantle cell lymphoma. <i>Journal of Cancer</i> , 2020, 11, 4980-4988.	1.2	4
571	Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice. <i>Expert Review of Hematology</i> , 2020, 13, 851-869.	1.0	2

#	ARTICLE	IF	CITATIONS
572	Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma. <i>Journal of Hematopathology</i> , 2020, 13, 231-238.	0.2	7
573	Minimal Residual Disease in Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 887-901.	0.9	10
574	Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma. <i>Clinical Journal of Oncology Nursing</i> , 2020, 24, 392-398.	0.3	7
575	Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk. <i>BMC Cancer</i> , 2020, 20, 1202.	1.1	3
576	<p><p>The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies â€“ Narrative Review<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2961-2977.	0.9	52
577	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the <sc>LYSA</sc> group. <i>Hematological Oncology</i> , 2020, 38, 446-455.	0.8	5
578	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	0.6	86
579	Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma. <i>Nuclear Medicine Communications</i> , 2020, 41, 540-549.	0.5	4
580	Treatment of Patients with Relapsed or Refractory Mantleâ€“Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. <i>Clinical Cancer Research</i> , 2020, 26, 4216-4224.	3.2	126
581	Management of Drug Resistance in Mantle Cell Lymphoma. <i>Cancers</i> , 2020, 12, 1565.	1.7	16
582	Emerging therapies in mantle cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 79.	6.9	33
583	Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi-institutional cohort in Taiwan. <i>International Journal of Hematology</i> , 2020, 112, 385-394.	0.7	2
584	Bortezomib maintenance after Râ€“CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. <i>British Journal of Haematology</i> , 2020, 190, 385-393.	1.2	11
585	Systematic literature review of the global burden of illness of mantle cell lymphoma. <i>Current Medical Research and Opinion</i> , 2020, 36, 843-852.	0.9	3
586	Genetic alterations in B cell lymphoma subtypes as potential biomarkers for non-invasive diagnosis, prognosis, therapy, and disease monitoring. <i>Turkish Journal of Biology</i> , 2020, 44, 1-14.	2.1	10
587	Mantle cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103038.	2.0	21
588	Mantle Cell Lymphoma of Mucosaâ€“Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. <i>HemaSphere</i> , 2020, 4, e302.	1.2	10
589	MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 2197-2208.	1.4	7

#	ARTICLE	IF	CITATIONS
590	Mantle cell lymphoma mimicking adult T-cell leukemia. <i>Pathology Research and Practice</i> , 2020, 216, 152825.	1.0	0
591	Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. <i>Bone Marrow Transplantation</i> , 2020, 55, 1076-1084.	1.3	20
592	An update on options of therapy for aggressive mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2036-2049.	0.6	0
593	<i><i>MYC<i> rearrangement but not extra <i>MYC<i> copies is an independent prognostic factor in patients with mantle cell lymphoma. <i>Haematologica</i> , 2021, 106, 1381-1389.	1.7	25
594	Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. <i>Leukemia</i> , 2021, 35, 130-142.	3.3	70
595	Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. <i>Blood</i> , 2021, 137, 877-887.	0.6	68
596	Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry. <i>Blood Reviews</i> , 2021, 47, 100778.	2.8	8
597	High-Risk Mantle Cell Lymphoma in the Era of Novel Agents. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 8-18.	1.2	5
598	LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome. <i>Blood</i> , 2021, 137, 3251-3258.	0.6	9
599	Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study. <i>Anticancer Research</i> , 2021, 41, 927-936.	0.5	5
600	Introduction to Non-Hodgkinâ€™s Lymphoma. , 2021, , 1-13.		0
601	Blastoid mantle cell lymphoma presenting as acute leukemia: a case report. <i>Pan African Medical Journal</i> , 2021, 39, 150.	0.3	0
602	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e34-e44.	2.2	29
603	Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study. <i>HemaSphere</i> , 2021, 5, e538.	1.2	52
604	Realâ€™world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. <i>Cancer Communications</i> , 2021, 41, 275-278.	3.7	4
605	Mantle cell lymphoma â€™ advances in molecular biology, prognostication and treatment approaches. <i>British Journal of Haematology</i> , 2021, 195, 162-173.	1.2	31
606	Infiltration of CD163â€™, PDâ€™L1â€™ and FoxP3â€™ positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. <i>British Journal of Haematology</i> , 2021, 193, 520-531.	1.2	12
607	Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma. <i>BMC Cancer</i> , 2021, 21, 209.	1.1	5

#	ARTICLE	IF	CITATIONS
608	Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival. <i>Blood Advances</i> , 2021, 5, 1638-1647.	2.5	8
609	Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions. <i>Journal of Clinical Medicine</i> , 2021, 10, 1207.	1.0	11
610	Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells. <i>Drugs</i> , 2021, 81, 669-684.	4.9	2
611	P300/CBP inhibition sensitizes mantle cell lymphoma to PI3KÎ inhibitor idelalisib. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 457-469.	2.8	10
612	Râ€MACLOâ€VAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma â€Long term follow up results. <i>American Journal of Hematology</i> , 2021, 96, 680-689.	2.0	1
613	Allogeneic stem cell transplantation for mantle cell lymphomaâ€”update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74). <i>Annals of Hematology</i> , 2021, 100, 1569-1577.	0.8	6
614	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	0.8	37
615	Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis. <i>British Journal of Haematology</i> , 2021, 194, 365-377.	1.2	13
616	Radiomics in Oncology, Part 2: Thoracic, Genito-Urinary, Breast, Neurological, Hematologic and Musculoskeletal Applications. <i>Cancers</i> , 2021, 13, 2681.	1.7	26
617	Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials. <i>Cancers</i> , 2021, 13, 2443.	1.7	4
618	Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome After High-Dose Chemotherapy. <i>Cancers</i> , 2021, 13, 2558.	1.7	2
619	A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 790-818.	1.0	6
620	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	1.1	3
621	Mantle cell lymphomaâ€”Advances in molecular biology, prognostication and treatment approaches. <i>Hematological Oncology</i> , 2021, 39, 31-38.	0.8	8
622	Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. <i>Leukemia</i> , 2022, 36, 177-188.	3.3	11
623	Il percorso diagnostico terapeutico assistenziale per la gestione delle sindromi linfoproliferative croniche nell'Ulss7 della regione Veneto: a che punto siamo?. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 0, , .	0.2	0
624	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021, 56, 2606-2609.	1.3	3
625	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. <i>Modern Pathology</i> , 2021, 34, 2183-2191.	2.9	7

#	ARTICLE	IF	CITATIONS
626	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021, 96, 1374-1384.	2.0	11
627	Non-chemotherapy Options for Newly Diagnosed Mantle Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 98.	1.3	1
628	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	2.5	21
629	Quadruple-hit pleomorphic mantle cell lymphoma with <i>MYC</i> , <i>BCL2</i> , <i>BCL6</i> , and <i>CCND1</i> gene rearrangements. <i>British Journal of Haematology</i> , 2021, 195, 634-637.	1.2	2
630	Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e648-e657.	2.2	27
631	Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2021, 14, 1-17.	1.0	2
632	Mantle Cell Lymphoma. <i>Hematologic Malignancies</i> , 2021, , 163-178.	0.2	0
633	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. <i>Cancers</i> , 2021, 13, 291.	1.7	17
634	Non-Hodgkin's Lymphoma. , 2010, , 583-592.		2
635	Soft Tissue and Lymph Nodes of the Head and Neck. , 2019, , 277-329.		1
636	Mantle Cell Lymphoma. , 2020, , 69-82.		1
637	Title is missing!. , 2017, , .		3
638	Title is missing!. , 2017, , .		1
639	Mantle Cell Lymphoma. , 2011, , 333-348.		8
640	Non-Hodgkin Lymphoma. , 2014, , 2033-2059.e8.		1
641	Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. <i>HemaSphere</i> , 2021, 5, e510.	1.2	18
642	Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 22.	0.9	6
643	Positron Emission Tomography in the Diagnosis and Monitoring of Lymphomas. <i>Medical Radiology and Radiation Safety</i> , 2018, 63, 41-50.	0.0	10

#	ARTICLE	IF	CITATIONS
644	Protein Kinase CK2 Inhibition Down Modulates the NF- κ B and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. PLoS ONE, 2013, 8, e75280.	1.1	75
645	Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG). Aging, 2019, 11, 8463-8473.	1.4	11
646	Gene mutations and actionable genetic lesions in mantle cell lymphoma. Oncotarget, 2016, 7, 58638-58648.	0.8	34
647	CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases. Oncotarget, 2018, 9, 11441-11450.	0.8	27
648	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. Haematologica, 2021, 106, 2940-2946.	1.7	11
649	NEGATIVE IMPACT OF THE TP53 GENE MUTATIONS ON THE EFFICACY OF THE THERAPY OF MANTLE CELL LYMPHOMA. INTERIM RESULTS OF THE MCL-2016 PROTOCOL. Gematologiya I Transfuziologiya, 2019, 64, 256-273.	0.1	2
650	Refractory mantle cell lymphoma in elderly patient - case report. Onkologie (Czech Republic), 2017, 11, 149-153.	0.0	1
651	Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement. World Journal of Gastroenterology, 2010, 16, 4661.	1.4	35
652	Staging and response assessment in lymphomas: the new Lugano classification. Chinese Clinical Oncology, 2015, 4, 5.	0.4	99
653	Indian Council of Medical Research consensus document for the management of non-hodgkin's lymphoma (high grade). Indian Journal of Medical and Paediatric Oncology, 2017, 38, 51.	0.1	4
654	Ill-fitting dentures as primary presentation of mantle cell lymphoma: A case report and literature review of the primary mantle cell lymphomas of the hard palate. Journal of Oral and Maxillofacial Pathology, 2015, 19, 255.	0.3	6
655	Diagnosis and treatment of mantle cell lymphoma. Swiss Medical Weekly, 2013, 143, w13868.	0.8	4
656	The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma. Chinese Journal of Cancer, 2012, 31, 348-353.	4.9	7
657	Ki-67 Labeling Indices in 'Classic' versus 'Blastoid' Mantle Cell Lymphomas - Proposed Cutoff Values for Routine Diagnostic Workup. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6591-6594.	0.5	4
658	Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma. PeerJ, 2017, 5, e3457.	0.9	11
659	A case of chronic lymphocytic leukemia with unmutated variable region of the immunoglobulin heavy chain gene with markedly high lactate dehydrogenase responding to ibrutinib. Journal of Applied Hematology, 2021, 12, 172.	0.1	0
660	Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T. Cancers, 2021, 13, 5181.	1.7	13
661	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Advances, 2022, 6, 1350-1360.	2.5	9

#	ARTICLE	IF	CITATIONS
662	Mimicking an Intraluminal Lesion: A Case Report on Mantle Cell Lymphoma. Cureus, 2021, 13, e18870.	0.2	0
663	Hodgkin Disease and Non-Hodgkin Lymphomas. , 2010, , 571-639.		0
664	Overview of the Lymphoid Neoplasms. , 2012, , 3-39.		0
666	Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leukemia and Lymphoma, 0, , 1-6.	0.6	0
667	Kapitel E1 Literaturverzeichnis zu Peter, Pichler, MÃ¼ller-Ladner (Hrsg.): Klinische Immunologie. , 2012, , e1-e80.		0
668	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
669	Small B-Cell Lymphomas. , 2012, , 205-260.		0
670	Indolente (niedrig maligne) Non-Hodgkin-Lymphome. , 2012, , 403-445.		0
671	Non-Hodgkin's Lymphoma. , 2012, , 1545-1572.		0
672	Lymphoma Surveillance Counterpoint: USA. , 2013, , 461-466.		0
673	Prognostic Factors in B-Cell Lymphomas. , 2013, , 101-139.		0
674	Gastrointestinal Mantle Cell Lymphoma: incidental finding on routine CT scan following pneumothorax.. Orthodontic Journal of Nepal, 2013, 2, 24-26.	0.0	0
675	Acknowledgments / The Authors. , 2013, , 295-295.		0
676	Lymphoma, Non-Hodgkinâ€™sâ†. , 2014, , .		0
677	Mantle Cell Lymphoma. , 2014, , 2646-2650.		0
678	Mantle Cell Lymphoma. , 2014, , 1-5.		0
679	Mantle Cell Lymphoma. , 2014, , 277-302.		0
680	The Challenge of Treating Elderly Patients with Mantle Cell Lymphoma. , 2015, , 143-168.		0

#	ARTICLE	IF	CITATIONS
681	Mantle Cell Lymphoma: Current Concepts. Journal of Hematology & Thromboembolic Diseases, 2015, 03, .	0.1	0
682	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
683	PET/CT for HL Staging. , 2016, , 1-13.		0
684	Radiation Therapy in the Management of Mantle Cell Lymphoma. , 2017, , 143-155.		0
685	Mantle cell lymphoma. , 2017, , 113-122.		0
686	Indolente (niedrig maligne) Non-Hodgkin-Lymphome. , 2017, , 437-484.		0
687	A Case of Mantle Cell Lymphoma Diagnosed in Mass of the Right Buccal Mucosa as a Primary Symptom. Japanese Journal of Oral Diagnosis / Oral Medicine, 2018, 31, 229-233.	0.0	0
688	Aggressive Lymphoma. , 2019, , 387-399.		0
690	Mantle cell lymphoma: Saudi Lymphoma Group's clinical practice guidelines for diagnosis, management and follow-up. Saudi Journal of Medicine and Medical Sciences, 2019, 7, 226.	0.3	1
691	Gastrointestinal Lymphomas. , 2019, , 329-349.		0
692	Exosome complex genes mediate RNA degradation and predict survival in mantle cell lymphoma. Oncology Letters, 2019, 18, 5119-5128.	0.8	8
694	Indolente (niedrig maligne) Non-Hodgkin-Lymphome. , 2020, , 463-512.		0
695	Blastoid Mantle Cell Lymphoma of the Palate: Report of a Rare Aggressive Entity and Review of the Literature. Head and Neck Pathology, 2022, 16, 631-642.	1.3	1
696	Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience. Hematological Oncology, 2022, 40, 23-31.	0.8	1
697	Mantle Cell Lymphoma: History, Current Principles of Diagnosis, and Treatment (Literature Review). Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 366-381.	0.1	0
698	First experience of allogeneic haematopoietic stem cell transplantation in patients with mantle cell lymphoma with a mutation in the TP53 gene. Gematologiya I Transfuziologiya, 2020, 65, 483-500.	0.1	1
699	Mantle Cell Lymphoma: Therapeutics and Management. Molecular and Translational Medicine, 2020, , 163-177.	0.4	0
700	An overlapping case of &in situ&mantle cell neoplasia and leukemic non-nodal mantle cell lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2020, 60, 169-173.	0.3	0

#	ARTICLE	IF	CITATIONS
701	Unusual location of recurrent mantle cell lymphoma on fluorodeoxyglucose-positron emission tomography despite complete metabolic resolution of previous sites of disease. <i>World Journal of Nuclear Medicine</i> , 2020, 19, 277.	0.3	0
702	Small B-Cell Lymphomas With and Without Plasmacytic Differentiation. , 2020, , 87-121.		0
703	Synergistic Effect and Tolerance of Concurrent Radiotherapy and Lenalidomide Use in Relapsing Mantle Cell Lymphoma: A Case Report. , 2020, 24, 1-6.		2
704	Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 655-666.	1.4	1
705	What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes?. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 825-835.	0.9	2
706	Mantle Cell Lymphoma: A North Indian Tertiary Care Centre Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 4583-4586.	0.5	4
708	Mantle cell lymphoma presenting with lethal atraumatic splenic rupture. <i>Autopsy and Case Reports</i> , 2021, 11, e2021340.	0.2	2
709	Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases. <i>Croatian Medical Journal</i> , 2021, 62, 455-463.	0.2	2
710	Advances in Lymphoma Molecular Diagnostics. <i>Diagnostics</i> , 2021, 11, 2174.	1.3	3
711	Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data. <i>Cancer Reports</i> , 2021, , e1590.	0.6	3
712	Sequencing of Novel Therapies for Mantle Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 118.	1.3	3
713	Survival and epidemiologic trends of lymphomas in Saudi Arabia: A 10-year report from a tertiary care hospital. <i>Saudi Journal of Medicine and Medical Sciences</i> , 2022, 10, 31.	0.3	3
714	Clinical characteristics and outcomes of ocular adnexal mantle cell lymphoma. <i>Orbit</i> , 2022, 41, 97-104.	0.5	1
715	Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands. <i>Clinical Cancer Research</i> , 2022, 28, 1628-1639.	3.2	6
716	Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?. <i>British Journal of Haematology</i> , 2022, 197, 139-155.	1.2	11
717	Artificial Intelligence Analysis of Gene Expression Predicted the Overall Survival of Mantle Cell Lymphoma and a Large Pan-Cancer Series. <i>Healthcare (Switzerland)</i> , 2022, 10, 155.	1.0	19
718	Lymphomas and Total Body Irradiation. , 2022, , 487-519.		0
719	Longitudinal CT Imaging to Explore the Predictive Power of 3D Radiomic Tumour Heterogeneity in Precise Imaging of Mantle Cell Lymphoma (MCL). <i>Cancers</i> , 2022, 14, 393.	1.7	4

#	ARTICLE	IF	CITATIONS
720	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	30
722	Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases. <i>Croatian Medical Journal</i> , 2021, 62, 455-463.	0.2	1
723	Prognostic Role of Pre-Treatment Metabolic Parameters and Sarcopenia Derived by 2-[18F]-FDG PET/CT in Elderly Mantle Cell Lymphoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 1210.	1.0	9
724	Ofatumumab plus HyperCVAD/HD+EMA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. <i>Cancer</i> , 2022, 128, 1595-1604.	2.0	2
725	A novel clinical immune-related prognostic model predicts the overall survival of mantle cell lymphoma. <i>Hematological Oncology</i> , 2022, 40, 343-355.	0.8	2
726	Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. <i>American Journal of Hematology</i> , 2022, 97, 638-656.	2.0	48
727	Stem cell transplant for mantle cell lymphoma in Taiwan. <i>Scientific Reports</i> , 2022, 12, 5662.	1.6	3
728	Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment. <i>Cancers</i> , 2022, 14, 141.	1.7	8
729	A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. <i>Cancers</i> , 2022, 14, 188.	1.7	6
730	Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study. <i>Cancer Medicine</i> , 2022, 11, 4134-4145.	1.3	3
731	Prognostic Value of Heterogeneity Index Derived from Baseline 18F-FDG PET/CT in Mantle Cell Lymphoma. <i>Frontiers in Oncology</i> , 2022, 12, 862473.	1.3	2
732	CAR T-Cell Therapy in the Older Person: Indications and Risks. <i>Current Oncology Reports</i> , 2022, 24, 1189-1199.	1.8	11
733	Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma. <i>Cancers</i> , 2022, 14, 2008.	1.7	14
734	Mantle cell lymphoma. , 0, , 308-337.		0
735	The pathologic diagnosis of mantle cell lymphoma. <i>Histology and Histopathology</i> , 2021, , 18351.	0.5	2
737	Mantle cell lymphoma-management in evolution. <i>Chinese Clinical Oncology</i> , 2015, 4, 8.	0.4	0
738	Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1164-1170.	1.3	4
739	New Directions for Mantle Cell Lymphoma in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 614-628.	1.8	14

#	ARTICLE	IF	CITATIONS
740	Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 4122-4131.	2.5	8
741	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 2482-2494.	13.9	83
742	Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. <i>Journal of Clinical Oncology</i> , 2023, 41, 541-554.	0.8	23
743	Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 2495-2506.	13.9	44
744	Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. <i>Blood</i> , 2022, 140, 1907-1916.	0.6	22
745	Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?. <i>Journal of Personalized Medicine</i> , 2022, 12, 1134.	1.1	1
746	Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research. <i>Leukemia</i> , 2022, 36, 2151-2164.	3.3	24
747	Prognostic value and computer image analysis of p53 in mantle cell lymphoma. <i>Annals of Hematology</i> , 2022, 101, 2271-2279.	0.8	1
748	Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial. <i>Leukemia</i> , 2022, 36, 2479-2487.	3.3	3
749	Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation. <i>Blood Advances</i> , 2023, 7, 866-874.	2.5	1
750	p53 immunohistochemistry must be confirmed by TP53 next generation sequencing for accurate risk stratification of patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 3504-3507.	0.6	3
751	Deep Learning-Based Nuclear Morphometry Reveals an Independent Prognostic Factor in Mantle Cell Lymphoma. <i>American Journal of Pathology</i> , 2022, , .	1.9	0
752	Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1614-1625.	1.3	4
753	[¹⁸ F]FDG-PET/CT volumetric parameters can predict outcome in untreated mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 0, , 1-10.	0.6	1
754	Combination of ibrutinib and venetoclax followed by Chimeric Antigen Receptor T-cell therapy in the first line of treatment in an elderly patient with mantle cell lymphoma with hyperleukocytosis and mutation in the TP53 gene. <i>Gematologiya I Transfuziologiya</i> , 2022, 67, 441-452.	0.1	0
755	Whole Transcriptome Sequencing Reveals Cancer-Related, Prognostically Significant Transcripts and Tumor-Infiltrating Immunocytes in Mantle Cell Lymphoma. <i>Cells</i> , 2022, 11, 3394.	1.8	1
756	Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic. <i>Annals of Hematology</i> , 2023, 102, 107-115.	0.8	2
757	Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors. <i>Haematologica</i> , 0, , .	1.7	0

#	ARTICLE	IF	CITATIONS
758	Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 131-145.	1.4	4
759	Extranodal manifestation of mantle cell lymphoma in the submandibular duct: A case report and review of literature. <i>Otolaryngology Case Reports</i> , 2023, 26, 100498.	0.0	0
760	Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. <i>Blood Advances</i> , 2023, 7, 2287-2296.	2.5	3
761	Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry. <i>Leukemia and Lymphoma</i> , 2023, 64, 621-627.	0.6	1
762	The Novel Prognostic Index Model of Combining Circulating Tumor DNA and PINK-E Predicts the Clinical Outcomes for Newly Diagnosed Extranodal NK/T-cell Lymphoma. <i>HemaSphere</i> , 2023, 7, e822.	1.2	2
763	The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium. <i>Journal of Clinical Oncology</i> , 2023, 41, 2076-2086.	0.8	11
764	Putting the brain into mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2023, 64, 259-260.	0.6	0
765	Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001. <i>Oncotarget</i> , 2023, 14, .	0.8	0
766	Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2023, 41, 2594-2606.	0.8	37
767	Treatment approaches for patients with TP53-mutated mantle cell lymphoma. <i>Lancet Haematology</i> , the, 2023, 10, e142-e154.	2.2	6
768	Personalized approaches for treatment-naïve mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2023, 16, 95-107.	1.0	0
769	Multicolor flow cytometric assessment of Ki67 expression and its diagnostic value in mature B-cell neoplasms. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
770	How I manage mantle cell lymphoma: indolent versus aggressive disease. <i>British Journal of Haematology</i> , 2023, 201, 185-198.	1.2	3
771	A Multicenter Analysis of the Outcomes with Venetoclax in Patients with Relapsed Mantle Cell Lymphoma. <i>Blood Advances</i> , 0, , .	2.5	1
772	Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers. <i>World Journal of Oncology</i> , 2023, 14, 4-14.	0.6	11
774	Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 599-605.	0.2	3
811	Mantelzellymphom. , 2023, , 179-196.		0
813	Mantle Cell Lymphoma. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
815	Indolente (niedrig maligne) Non-Hodgkin-Lymphome. , 2024, , 491-544.		0